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Background. The World Health Organization Antiretroviral Treatment Guidelines recommend phasing-out stavudine because
of its risk of long-term toxicity. There are two mutational pathways of stavudine resistance with different implications for zidovudine
and tenofovir cross-resistance, the primary candidates for replacing stavudine. However, because resistance testing is rarely available
in resource-limited settings, it is critical to identify the cross-resistance patterns associated with ﬁrst-line stavudine failure.
Methods. We analyzed HIV-1 resistance mutations following ﬁrst-line stavudine failure from 35 publications comprising 1,825
individuals. We also assessed the inﬂuence of concomitant nevirapine vs. efavirenz, therapy duration, and HIV-1 subtype on the
proportions of mutations associated with zidovudine vs. tenofovir cross-resistance.
Results. Mutations with preferential zidovudine activity, K65R or K70E, occurred in 5.3% of individuals. Mutations with prefer-
ential tenofovir activity, ≥two thymidine analog mutations (TAMs) or Q151M, occurred in 22% of individuals. Nevirapine in-
creased the risk of TAMs, K65R, and Q151M. Longer therapy increased the risk of TAMs and Q151M but not K65R. Subtype C and
CRF01_AE increased the risk of K65R, but only CRF01_AE increased the risk of K65R without Q151M.
Conclusions. Regardless of concomitant nevirapine vs. efavirenz, therapy duration, or subtype, tenofovir was more likely than
zidovudine to retain antiviral activity following ﬁrst-line d4T therapy.
Keywords. HIV-1; drug resistance; mutations; nucleoside reverse transcriptase inhibitor; NRTI; stavudine; d4T; zidovudine;
AZT; tenofovir; TDF; subtypes.
The global scale-up of antiretroviral (ARV) therapy has dra-
matically reduced human immunodeﬁciency virus (HIV)
morbidity and mortality. Stavudine (d4T) has been among
the most commonly used ARVs in resource-limited settings
because of its efﬁcacy, short-term tolerability, low cost, and
availability in coformulated form. However, many countries
are transitioning away from d4T, mainly because of mito-
chondrial toxicities associated with long-term d4T use. In
2010, the World Health Organization (WHO) recommended
phasing out d4T even in patients without documented viro-
logical failure [1].
There are two distinct mutational pathways of d4T resis-
tance with different implications for zidovudine (AZT) and
tenofovir (TDF) cross-resistance, the primary candidates for
replacing d4T [2–4]. However, genotypic resistance testing is
usually not available in the resource-limited settings where
d4T-containing regimens are most commonly used. It is
therefore important to determine the extent of nucleoside
reverse-transcriptase inhibitor (NRTI) cross-resistance in
viruses from individuals with virological failure on d4T-con-
taining ﬁrst-line therapy undergoing genotypic resistance
testing. In this study, we combined genetic sequence data
from 35 different studies to characterize the patterns of NRTI
resistance mutations in viruses from individuals with viro-
logical failure on the 2 widely used d4T-containing ARV regi-
mens: d4T/lamivudine(3TC)/nevirapine(NVP) and d4T/3TC/
efavirenz(EFV). We also examine the effects of HIV-1
subtype, duration of therapy, and concomitant nonnucleoside
reverse-transcriptase inhibitor (NNRTI) on the selection of
speciﬁc mutations. We focused our analysis on NRTI resis-
tance mutations with differential effects on the residual activi-
ty of AZT compared with TDF. The implications of these
data for optimal replacement of d4T and subsequent NRTI
options are discussed.
METHODS
First-Line ARV Therapy and HIV-1 Reverse Transcriptase (RT)
Sequences
We analyzed the RT sequences of HIV-1 isolates from individu-
als in the Stanford HIV Drug Resistance Database (HIVDB) who
received ﬁrst-line therapy with either d4T/3TC/NVP or d4T/
3TC/EFV [5]. RT sequences were eligible for analysis if they were
reported in a peer-reviewed publication that contained ≥5 RT se-
quences from previously ARV-naive individuals receiving 1 of
the 2 ﬁrst-line d4T-containing regimens. For individuals from
whommultiple RT sequences were available, the last sequence on
therapy was used in our analyses.
NRTI Resistance Mutations
Mutations were deﬁned as differences from the subtype B con-
sensus sequence (http://hivdb.stanford.edu/DR/asi/releaseNotes/
index.html#consensusbsequences). NRTI resistance mutations
included the 34 surveillance drug-resistance mutations at 16
RT positions (M41L, K65R, D67NGE, T69D, T69insertions,
K70RE, L74VI, V75MTAS, F77L, Y115F, F116Y, Q151M,
M184VI, L210W, T215YFISCDVE, K219QERN) [6] and
several less common NRTI resistance mutations, including
K65N, T69deletions, and K70QG. Mutations at the same posi-
tion with similar effects on NRTI susceptibility were pooled, in-
cluding K65RN, D67NG, K70EGQ, L74VI, M184VI, T215YF,
and K219QE. Thymidine analog–associated mutations (TAMs)
were deﬁned as M41L, D67NG, K70R, L210W, T215YF, and
K219QE. Type 1 TAMs, which are associated with higher levels
of reduced susceptibility to both AZT and TDF, include M41L,
L210W, and T215Y.
We focused on NRTI resistance mutations with different im-
plications for AZTand TDF cross-resistance. Themost common
of these mutations include (1) K65R, which reduces TDF
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susceptibility but increases AZT susceptibility; (2) TAMs, which
reduce AZT susceptibility more than they reduce TDF suscepti-
bility; (3) Q151M, which confers high-level AZT resistance and
intermediate TDF resistance; and (4) K70EGQ, which is a rare
mutation that reduces susceptibility to TDF but not AZT. K65R
often occurs in combination with Q151M and has different im-
plications for cross-resistance depending on whether it occurs
alone or with Q151M [7]. Indeed, the combination of K65R plus
Q151M is associated with high-level resistance to both AZT and
TDF. In contrast, K65R and the TAMs are usually mutually ex-
clusive [3, 7]. The most commonly occurring NRTI resistance
mutation, M184VI, which increases susceptibility to both AZT
and TDF, was also included in our analysis [4].
Based on the phenotypic correlates of these mutations,
viruses with K65RN or K70EGQ in the absence of Q151M
were considered to be preferentially inhibited by AZT. K65R is
the most important of these because it is the primary mutation
selected in vivo by TDF and because it increases AZT activity
in vivo as well as in vitro [8, 9]. Viruses with ≥2 TAMs were
considered to be preferentially inhibited by TDF. Although
viruses with a single TAM may also be preferentially inhibited
by TDF, the relative beneﬁt of TDF compared with AZT
against viruses with a single TAM is unlikely to be as great as
the relative beneﬁt of AZT compared with TDF in the treat-
ment of viruses with K65R.
The T215 revertant mutations, T215SCDEIV, were excluded
from analysis because they occurred much less frequently than
the TAMs T215YF and because they have little if any effect on
NRTI susceptibility [10]. The Q151M accessory mutations
A62V, V75I, F77L, and F116Y were excluded because they oc-
curred rarely in the absence of Q151M. The multi–NRTI resis-
tance insertions and deletions at position 69 were excluded
because T69 insertions occurred in just 2 individuals, and, al-
though T69 deletions occurred in 23 individuals, they occurred
solely in combination with K65R and/or Q151M. Although
Y115F is associated with reduced TDF susceptibility, it was not
included because it occurred rarely and because its effect on
AZT susceptibility is not well characterized [11].
An additional analysis compared the estimated reductions in
susceptibility to AZT and TDF using the HIVDB drug resis-
tance interpretation system. Each submitted sequence was char-
acterized as susceptible, potentially low-level resistant, low-level
resistant, intermediately resistant, or highly resistant to AZT
and TDF. In contrast with the analysis of mutation frequencies,
this analysis takes into account the varying effects of speciﬁc
TAMs on AZT and TDF susceptibility. For this analysis, the
potentially low-level resistant category was pooled with the sus-
ceptible category.
Concomitant NNRTI, Duration of Therapy, and HIV-1 Subtype
We sought to determine whether the proportions of different
mutations were inﬂuenced by the following variables: (1) the
concomitantly administered NNRTI (NVP compared with
EFV); (2) the duration of ﬁrst-line d4T-containing therapy; and
(3) the HIV-1 subtype. The number of weeks of therapy was
known for about one-third of the individuals in the study. For
the remaining individuals, the median number of weeks of
therapy for all individuals in a study was used. Duration of
therapy was classiﬁed as 1 year for individuals with up to 52
weeks of therapy, 2 years for those with 53–104 weeks of
therapy, 3 years for those with 105–156 weeks of therapy, and 4
years for those with >156 weeks of therapy. HIV-1 subtype was
determined primarily by using the automated Rega Institute
subtyping tool [12]. For indeterminate results, subtype was de-
termined using Los Alamos National Laboratories HIV Data-
base jumping proﬁle hidden Markov model algorithm [13].
We used stepwise forward logistic regression to assess the in-
ﬂuence of ARV duration, NNRTI, and subtype on the following
10 mutation categories using the R step function [14]: M184VI
(henceforth, M184V), ≥1 TAM (TAMsGE1), ≥2 TAMs
(TAMsGE2), ≥3 TAMs (TAMsGE3), ≥1 type 1 TAM (Type1-
TAMsGE1), ≥2 type 1 TAMs (Type1TAMsGE2), three type 1
TAMs (Type1TAMs3), K65RN without Q151M (K65R alone),
Q151M without K65RN (Q151M alone), and K70EGQ (hence-
forth, K70E). Because previous published studies of K65R have
not distinguished between those with and without Q151M, we
also performed separate logistic regression models to examine
the effects of ARV duration, NNRTI, and subtype on the pro-
portion of viruses with this mutation.
RESULTS
Summary of Analyzed Studies
Thirty-ﬁve studies comprising 1825 individuals receiving ﬁrst-
line ART with d4T/3TC/NVP or d4T/3TC/EFV were analyzed.
Sixty-ﬁve percent (1182 individuals) were from 13 countries in
sub–Saharan Africa. Twenty-three percent (417 individuals)
were from the Southeast Asian countries of Thailand and Cam-
bodia. The remaining 12% of individuals were from the United
States (117 individuals), India (86 individuals), China (14 indi-
viduals), and Europe (7 individuals). Adults and children com-
prised at least 75% and 7% of the study population,
respectively; the age group was not available for the remaining
18% of the study population. A prior history of single-dose ne-
virapine was noted for <80 individuals from 5 studies.
The median duration of therapy per study was 72 weeks (in-
terquartile range, 52–104 weeks). Sixty-seven percent of indi-
viduals received d4T/3TC/NVP, and 33% received d4T/3TC/
EFV. The most common subtypes were C (42.3% of individu-
als), CRF01_AE (AE; 23.6%), CRF02_AG (AG; 9.0%), B
(7.2%), G (6.5%), and A (5.5%). The majority of isolates from
subtype C, AE, and B were from individuals living in sub–
Saharan Africa (89%), Southeast Asia (97%), and the United
States (86%) respectively. More than 95% of AG, subtype A,
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and subtype G isolates were from individuals in sub–Saharan
Africa. Supplementary Table 1 summarizes the contribution of
each reference to the dataset.
The 10 categories of NRTI resistance mutations occurred in
the following proportions of the 1825 individuals: 72% for
M184V, 31% for TAMsGE1, 19% for TAMsGE2, 12% for
TAMsGE3, 12% for Type1TAMsGE1, 5.8% for Type1-
TAMsGE2, 2.1% for Type1TAMs3E3, 4.5% for K65R alone,
2.9% for Q151M alone, and 0.8% for K70E. Overall, K65R oc-
curred in 6.2% of individuals: 4.5% alone and 1.7% with
Q151M. Supplementary Table 2 contains the proportion of
each NRTI resistance mutation and mutation category for the
complete dataset and for subsets determined by the NNRTI
used, duration of therapy in years, and HIV-1 subtype.
NRTI Resistance Mutation Prevalence: Inﬂuence of
Concomitant NNRTI, Duration of ART, and HIV-1 Subtype
Figure 1 illustrates the proportion of individuals with 2 catego-
ries of mutations according to the covariables of HIV-1
subtype, concomitant NNRTI, and duration of therapy. It also
shows the number of individuals sharing the same covariable
pattern at the base of each plot. In the ﬁgure, K65R includes the
the presence of K65R or K70E, the mutations associated with
increased AZT susceptibility and decreased TDF susceptibility.
The 2 categories of TAMs in the ﬁgure are associated with
greater reductions in susceptibility to AZT than to TDF.
Q151M alone, which occurred in 2.9% of individuals and is
also associated with a greater reduction in susceptibility to AZT
than to TDF, is not shown. K65R occurred in 5%–10% of NVP-
treated individuals with subtype C, CRF01_AE, and subtype A
viruses; however, a much higher proportion of NVP-treated in-
dividuals with these subtypes had viruses with ≥2 TAMs.
Table 1 summarizes the results of stepwise logistic regression
modeling to assess the inﬂuence of the concomitant NNRTI,
duration of therapy, and subtype on the 10 categories of NRTI
resistance mutations. M184V, the TAMs, and Q151M were
positively associated with a longer duration of ART and the use
of NVP (as opposed to EFV). M184V and the TAMs were neg-
atively associated with subtype B. K65R alone was associated
only with CRF01_AE. In contrast, K65R with and without
Q151M was positively associated with NVP, subtype C, and
CRF01_AE and negatively associated with subtype B.
Estimated Levels of AZT and TDF Cross-resistance According to
the HIVDB Interpretation System
To estimate the levels of AZT and TDF cross-resistance, we
submitted the 1825 RT sequences to the HIVDB resistance in-
terpretation program. Sixty-seven percent (1225) of the se-
quences were categorized as susceptible to both AZT and TDF;
33% (600) were categorized as having decreased susceptibility
to either AZT and/or TDF. Figure 2 summarizes the HIVDB
interpretations for the entire set of these 600 sequences (upper
left plot), the 212 subtype C isolates (upper right plot), the 184
CRF01_AE isolates (lower left plot), and the 194 isolates be-
longing to the remaining subtypes (lower right plot).
In each plot, a higher proportion of viruses were estimated to
be more susceptible to TDF than to AZT (the circles to the
right of the diagonal). Among the entire set of 600 isolates with
decreased susceptibility to AZT and/or TDF, 41 (6.8%) were
equally susceptible to AZT and TDF, 91 (15.2%) were more
susceptible to AZT than TDF, and 468 (78%) were more sus-
ceptible to TDF than AZT. Fifty of the 51 isolates categorized
as intermediately resistant to TDF but susceptible to AZT had
K65R in the absence of Q151M.
DISCUSSION
During the global ARV scale-up, d4T-containing regimens
have been the most common initial ARV regimens used by
Figure 1. Proportion of viruses with 3 categories of nucleoside reverse-
transcriptase inhibitor mutations according to subtype, concomitant
nonnucleoside reverse-transcriptase inhibitor (NNRTI), and years of antire-
troviral therapy. The K65R category includes viruses with K65R but not
Q151M. It also includes a small number of viruses with K65N or K70EGQ.
Thymidine analog mutations include M41L, D67NG, K70R, L210W,
T215YF, and K219QE. The numbers of viruses with each covariable pattern
(subtype, NNRTI, and year) are shown at the base of each plot. Sequences
were available from 31 subtype A, 7 CRF02_AG, and 2 subtype G viruses
from individuals who received stavudine/lamivudine + efavirenz. Plots of
data from these 40 individuals are not shown. Abbreviations: NVP, individ-
uals receiving stavudine/lamivudine/nevirapine; EFV, individuals receiving
stavudine/lamivudine/efavirenz.
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many national HIV treatment programs. Although these regi-
mens are efﬁcacious in a high proportion of HIV-1–infected
patients, the numbers of patients developing virological failure
while receiving a d4T-containing regimen is steadily increasing
and necessitates the use of second-line treatment regimens [15–
18]. In addition, the potential for serious toxicity associated
with the long-term use of d4T has led the WHO to recommend
phasing out d4T for ﬁrst-line therapy [1].
The genetic mechanisms of d4T resistance are relevant to the
selection of the NRTIs used as part of a second-line ART
regimen and are also considerations for the choice of NRTIs to
be substituted for d4T in patients without known virological
failure. The most commonly occurring mutations with different
implications for AZT and TDF cross-resistance include the
TAMs, K65R, and Q151M. The TAMs reduce susceptibility to
both AZT and TDF; however, TDF retains signiﬁcant antiretro-
viral activity unless three type 1 TAMs are present [19]. In con-
trast, K65R reduces susceptibility to TDF while increasing
susceptibility to AZT [4]. Q151M confers high-level AZT and
intermediate TDF resistance. K65R and Q151M often occur in
combination and in this context cause high-level resistance to
both AZT and TDF [11]. As a result of the dichotomy between
the TAM and K65R pathways, the frequency with which K65R
occurs in the absence of Q151M largely determines the
proportions of individuals likely to respond to subsequent
therapy with AZT or TDF.
After combining data from 35 publications comprising 1825
individuals from whom RT sequences were available, we esti-
mated the relative proportions of NRTI resistance mutations
occurring in patients receiving d4T and assessed the inﬂuence
of concomitant NNRTI, duration of therapy, and subtype on
these estimates. Our analysis showed that the mutation pat-
terns associated with increased susceptibility to AZT relative to
TDF—K65R alone and less commonly K70E—occurred in
5.3% of individuals, whereas those associated with increased
susceptibility to TDF relative to AZT—≥2 TAMs or Q151M
alone—occurred in 22% of individuals. Q151M occurred nearly
as commonly as K65R in patients receiving prolonged d4T
therapy.
Several factors inﬂuenced the likelihood of speciﬁc NRTI resis-
tance mutations. The use of NVP (vs EFV) was associated with
increased proportions of M184V, TAMs, K65R, and Q151M. The
number of years of therapy was associated with increased propor-
tions of M184V, TAMs, and Q151M but not K65R. Subtype B
was associated with a decreased proportion of all mutations, but
this is almost certainly a result of frequent virological monitoring
of these individuals who were each from the United States [20,
21]. Subtype C was associated with an increased proportion of
Table 1. Logistic Regression Models For Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations: Inﬂuence of Treatment Du-
ration, Nonnucleoside Reverse-Transcriptase Inhibitor (nevirapine vs efavirenz), and Subtype (odds ratios and 95% conﬁdence intervals)
Mutation Model Years NVP C AE B
M184V Years + NVP +B 1.3 (1.2–1.5) 1.7 (1.4–2.1) . . . . . . 0.4 (0.3–0.6)
P= 3E−5 P< 1E−6 . . . . . . P< 1E−6
TAMsGE1 Years + NVP +B 1.7 (1.5–1.9) 1.7 (1.4–2.2) . . . . . . 0.2 (0.1–0.4)
P< 1E−6 P= 5E−6 . . . . . . P= 1E−6
TAMsGE2 Years + NVP +B 1.8 (1.5–2.0) 2.3 (1.7–3.2) . . . . . . 0.3 (0.2–0.7)
P< 1E−6 P< 1E−6 . . . . . . P= .002
TAMsGE3 Years + NVP +B 1.8 (1.5–2.1) 2.4 (1.6–3.5) . . . . . . 0.3 (0.1–0.8)
P< 1E−6 P= 7E−6 . . . . . . P= .01
Type1TAMsGE1 Years + NVP +B 1.7 (1.4–2.0) 2.0 (1.4–2.8) . . . . . . 0.4 (0.2–0.8)
P< 1E−6 P= 1E−4 . . . . . . P= .01
Type1TAMsGE2 Years + NVP +B 1.9 (1.5–2.4) 2.1 (1.2–3.5) . . . . . . 0.2 (0.1–0.9)
P< 1E−6 P= .006 . . . . . . P= .03
Type1TAMsE3 Years 1.8 (1.3–2.6) . . . . . . . . .
P= 9E−4 . . . . . . . . . . . .
K65R alone AE . . . . . . . . . 1.7 (1.1–2.8)
. . . . . . . . . P= .03
Q151M alone Years + NVP 1.7 (1.2–2.3) 3.6 (1.5–8.6) . . . . . .
P= 7E− 4 P= .005 . . . . . .
K65R often occurred in combination with Q151M (Supplemental Table 2). Because K65R and Q151M have different implications for treatment with zidovudine vs
tenofovir, we examined only those cases in which K65R occurred without Q151M (K65R alone) and those cases in which Q151M occurred without K65R (Q151M
alone). K65R included a small number of patients with K65N. There were no significant predictors of the rare mutation K70E (K70E ± K70G ± K70Q).
Abbreviations: M184V, (M184V ±M184I); NVP, nevirapine; TAMs, thymidine analog mutations (M41L, D67NG, K70R, L210W, T215YF, K219QE); TAMsGE1 (≥1
TAM); Type1TAMsGE1 (≥1 type 1 TAMs [type 1 TAMs: M41L, L210W, T215Y]).
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K65R, but only CRF01_AE was associated with K65R in the
absence of Q151M. However, regardless of the combination of
concomitant NNRTI, duration of therapy, or subtype, TDF was
more likely than AZT to retain antiviral activity against viruses
emerging during a ﬁrst-line d4T-containing regimen.
Subtype C viruses have a unique pattern of 5 consecutive
adenosines preceding the position of the mutation responsible
for K65R. This nucleic acid template predisposes subtype C
viruses to an increased frequency of K65R in biochemical and
in vitro passage experiments [22–24]. However, K65R did not
occur at a higher rate in subtype C viruses compared with
CRF01_AE or subtype A viruses. In contrast, the NNRTI resis-
tance mutation V106M, which is preferentially selected in
subtype C viruses as a result of a codon bias at position 106, oc-
curred in 21% of subtype C viruses but in <1% of viruses from
other subtypes, indicating that this study was powered to detect
meaningful intersubtype differences in mutation frequency.
Our study has 2 main limitations that might inﬂuence the es-
timated relative beneﬁt of AZT compared with TDF in different
clinical scenarios. Because the duration of therapy for most in-
dividuals was the median duration for the study rather than the
precise duration for the individual, we were not able to identify
individuals with rapid virological failure. Such individuals may
be more likely to have viruses with K65R because this mutation
results from a single nucleotide change. Moreover, K65R was
the only mutation in our analysis that did not increase in fre-
quency with the duration of therapy. A second limitation is the
possibility that undocumented substitutions of d4T for AZT
(eg, for toxicity or intolerance) may have biased our ﬁndings
because any prior therapy with AZT would increase the likeli-
hood of TAMs on a d4T-containing regimen.
In regions where routine virus load testing is available, d4T-
treated patients with stable virological suppression can be
switched either to AZT or TDF. However, TDF is likely to be
preferable because it has fewer toxicities and can be adminis-
tered once daily. In these same regions, d4T-treated patients
with virological failure can be identiﬁed and changed to a
second-line boosted protease inhibitor–containing treatment
regimen. In settings where genotypic resistance testing is avail-
able, the subset of patients for whom AZT is likely to be more
effective than TDF can be identiﬁed. However, in regions where
genotypic resistance testing is not available, our study suggests
Figure 2. Summary of the zidovudine (AZT) and tenofovir (TDF) drug resistance estimates reported by the Stanford HIV Drug Resistance Database
(HIVDB) drug resistance interpretation system (http://hivdb.stanford.edu; accessed 10 December 2012). Each of the 4 subplots indicates the numbers of
individuals having viruses with 16 different resistance proﬁles according to a 4-tiered susceptibility estimate: susceptible, low-level resistance (low-level),
intermediate resistance (intermediate), and high-level resistance. The HIVDB drug resistance interpretation system also contains a ﬁfth tier, potential low-
level resistance, but for this analysis these viruses were reclassiﬁed as susceptible. The number of viruses estimated to be susceptible to both AZT and
TDF is not shown but can be calculated from the total number of viruses in each category minus the sum of the remaining 15 categories. Abbreviations:
AZT, zidovudine; TDF, tenofovir.
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that TDF is more likely to be effective than AZT as part of a
second-line treatment regimen.
In regions where virus load testing is not available, it will not
be known whether virus levels are suppressed at the time d4T is
switched to AZT or TDF. Based on the reported high virologi-
cal responses to d4T-containing ﬁrst-line ARV regimens, it is
expected that the majority of adherent adult patients receiving
a ﬁrst-line d4T-containing regimen will be virologically sup-
pressed at the time d4T is switched [18, 25]. Because of its fa-
vorable toxicity proﬁle, TDF will usually be preferable to AZT
in these patients. In patients without virological suppression, a
single NRTI substitution is unlikely to achieve virological re-
suppression. However, TDF will be more likely than AZT to
retain residual antiviral activity against emerging drug-resistant
variants.
In conclusion, this study strongly suggests that whether pa-
tients are switched off of d4T as a result of virological failure or
to avoid long-term toxicities, TDF will be more advantageous
than AZT for the majority of patients in regions where geno-
typic resistance testing is not available.
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